Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.45 |
| ▸ | BTK | Q06187 | 4/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.43 |
| ▸ | KDR | P35968 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 3/20 | 0.40 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.40 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2450655 | 0.83 | RET (0.69) | RETKDR | |
| SCHEMBL2450652 | 0.83 | RET (0.69) | RETKDR | |
| SCHEMBL2455549 | 0.82 | KDR (0.49) | RETBTKSRD5A2KDREGFR | |
| SCHEMBL2448477 | 0.81 | RET (0.65) | RETKDR | |
| SCHEMBL2451247 | 0.80 | MAOB (0.48) | RETKDREGFRGAA | |
| SCHEMBL2450638 | 0.78 | RET (0.54) | RETKDR | |
| SCHEMBL838399 | 0.75 | TRPA1 (0.47) | POLBEGFRGAAMAP3K7TAB1 | |
| SCHEMBL2453347 | 0.74 | ALDH1A1 (0.46) | RETKDR | |
| SCHEMBL2453267 | 0.72 | RET (0.74) | RETKDR | |
| SCHEMBL2454668 | 0.72 | RET (0.74) | RETKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013153-B2 | Substituted pyrimidine kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-09-06 | — | — | US | disclosed |
| US-20070254896-A1 | SUBSTITUTED PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-01 | — | — | US | disclosed |
| WO-2007109783-A2 | SUBSTITUTED PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254896-A1 | SUBSTITUTED PYRIMIDINE KINASE INHIBITORS | DTYMK, TK1, DCK | RET 577/4885BTK 287/4885STS 2953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.